PREDICTING THE POTENTIAL FOR CANNABIDIOL INDUCED DRUG-DRUG INTERACTIONS WITH MAJOR CYP450 ENZYMES USING MODEL-BASED APPROACHES

被引：0
|
作者：
Eltanameli, B. [1 ]
Al Sahlawi, S. [1 ]
Cicali, B. [1 ]
Cristofoletti, R. [1 ]
机构：
[1] Univ Florida, Coll Pharm, Orlando, FL USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
LB-032
引用
收藏
页码：S37 / S38
页数：2
相关论文
共 50 条
  • [31] Modulatory Effects of Atractylodin and β-Eudesmol on Human Cytochrome P450 Enzymes: Potential Drug-Drug Interactions
    Thiengsusuk, Artitaya
    Plengsuriyakarn, Tullayakorn
    Na-Bangchang, Kesara
    MOLECULES, 2023, 28 (07):
  • [32] In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor
    Zhang, Heather
    Ou, Ying C.
    Su, Dan
    Wang, Fan
    Wang, Lai
    Sahasranaman, Srikumar
    Tang, Zhiyu
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2021, 9 (06):
  • [33] Predicting Drug-Drug Interactions Using Meta-path Based Similarities
    Tanvir, Farhan
    Islam, Muhammad Ifte Khairul
    Akbas, Esra
    2021 IEEE CONFERENCE ON COMPUTATIONAL INTELLIGENCE IN BIOINFORMATICS AND COMPUTATIONAL BIOLOGY (CIBCB), 2021, : 230 - 237
  • [34] Mechanism-based Inhibition of CYP450: An Indicator of Drug-induced Hepatotoxicity
    Feng, Shan
    He, Xin
    CURRENT DRUG METABOLISM, 2013, 14 (09) : 921 - 945
  • [35] Model-based assessments of CYP3A-mediated drug-drug interaction risk of milademetan
    Hong, Ying
    Ishizuka, Tomoko
    Watanabe, Akiko
    Tachibana, Masaya
    Lee, Mark
    Ishizuka, Hitoshi
    LaCreta, Frank
    Abutarif, Malaz
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (06): : 2220 - 2230
  • [36] Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model-Based Approaches to Drug-Drug Interaction Trial Design
    Reitman, M. L.
    Chu, X.
    Cai, X.
    Yabut, J.
    Venkatasubramanian, R.
    Zajic, S.
    Stone, J. A.
    Ding, Y.
    Witter, R.
    Gibson, C.
    Roupe, K.
    Evers, R.
    Wagner, J. A.
    Stoch, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 (02) : 234 - 242
  • [37] Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model
    Yamazaki, Shinji
    Johnson, Theodore R.
    Smith, Bill J.
    DRUG METABOLISM AND DISPOSITION, 2015, 43 (10) : 1417 - 1429
  • [38] Eslicarbazepine Acetate Drug-Drug Interactions: Characterization Through a Model-Based Population Approach
    Sunkaraneni, S.
    Ludwig, E. A.
    Blum, D.
    Fiedler-Kelly, J.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2015, 42 : S83 - S83
  • [39] Effectiveness of a large language model in predicting potential drug-drug interactions of multiple sclerosis patients
    Jahani, Shima
    Majidi, Marziyeh
    Toulabi, Sadegh
    Bafrani, Melika Arab
    Sahraian, Mohammad Ali
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1047 - 1047
  • [40] A novel model for the prediction of drug-drug interactions in humans based on in vitro CYP phenotypic data
    Lu, Chuang
    Miwa, Gerald T.
    Prakash, Shimoga
    Balani, Suresh K.
    DRUG METABOLISM REVIEWS, 2006, 38 : 100 - 100
12345